Tenax Therapeutics (TENX) News and press releases

Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

31 May 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

31 May 23

Movers

Tenax Therapeutics Achieves Major Milestone As USPTO Grants Notice Of Allowance For U.S. Patent Application Covering Use Of Oral Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction

31 May 23

News, Penny Stocks, Legal

Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030

Watching Tenax Therapeutics; Zacks Small-Cap Research Sets $5 Price Valuation

22 May 23

Biotech, News, Analyst Ratings, Trading Ideas, General

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_05222023_TENX_Vandermosten.pdf

Stocks That Hit 52-Week Lows On Wednesday

26 Apr 23

Options

On Wednesday, 345 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

24 Apr 23

Options

On Monday, 147 stocks made new 52-week lows.

Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure

12 Apr 23

Biotech, News, Penny Stocks, Health Care, General

Stocks That Hit 52-Week Lows On Wednesday

5 Apr 23

Options

On Wednesday, 220 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

3 Apr 23

Options

On Monday, 76 companies set new 52-week lows.

Tenax Therapeutics Announces Issuance Of U.S. Patent Covering Use Of IV Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction; Shares Move Higher

22 Mar 23

Biotech, News, FDA, General

Patent provides intellectual property protection until December 2040 PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030 There are

Tenax Therapeutics Will Be Issued U.S. Patent Number 11,607,412 Tomorrow Titled "Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction"

20 Mar 23

Biotech, News, FDA, General

Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

13 Mar 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.

12 Health Care Stocks Moving In Monday's Pre-Market Session

13 Mar 23

Movers

Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket

13 Mar 23

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.

12 Health Care Stocks Moving In Friday's Intraday Session

10 Mar 23

Movers

Stocks That Hit 52-Week Lows On Wednesday

8 Mar 23

Options

On Wednesday, 116 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

7 Mar 23

Options

On Tuesday, 93 companies set new 52-week lows.

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023

7 Mar 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

7 Mar 23

Movers

Roth MKM Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $6

7 Mar 23

News, Price Target, Initiation, Analyst Ratings

Roth MKM analyst Jonathan Aschoff initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Buy rating and announces Price Target of $6.

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

31 May 23

News, Health Care, Legal, Press Releases

Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved treatments for

Tenax Therapeutics Provides 2023 Business Update

12 Apr 23

Press Releases, General

Company to prioritize the clinical development of TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF)PH-HFpEF affects more than 1,600,000

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

22 Mar 23

News, Legal, Press Releases, General

Patent provides intellectual property protection until December 2040PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030There are currently